Study S002343

Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia: "The GOLD-Study"

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02770885
Acronym: GOLD
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 50
Start: 2016-03
Primary completion: 2019-05-17
Lead sponsor: University Hospital, Basel, Switzerland
Conditions: Primary Polydipsia
Interventions: DRUG:Dulaglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Fluid intake in ml [8 hours]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0006214	Effect of a 3-Week Treatment with GLP-1 Receptor Agonists on Vasoactive Hormones in Euvolemic Participants. Vukajlovic T, The Journal of clinical endocrinology and metabolism	2022	Randomized trial	PMID 35134170 DOI	cites ClinicalTrials.gov:NCT02770885; registry reference DERIVED:35134170
R0013314	A randomized controlled trial of the GLP-1 receptor agonist dulaglutide in primary polydipsia. Winzeler B, The Journal of clinical investigation	2021	Randomized trial	PMID 34473645 DOI	cites ClinicalTrials.gov:NCT02770885; registry reference DERIVED:34473645